{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T06:18:41Z","timestamp":1772173121932,"version":"3.50.1"},"update-to":[{"DOI":"10.1371\/journal.pcbi.1009978","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2022,4,6]],"date-time":"2022-04-06T00:00:00Z","timestamp":1649203200000}}],"reference-count":37,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2022,3,25]],"date-time":"2022-03-25T00:00:00Z","timestamp":1648166400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","award":["001"],"award-info":[{"award-number":["001"]}],"id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","award":["001"],"award-info":[{"award-number":["001"]}],"id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["315854\/2020-0"],"award-info":[{"award-number":["315854\/2020-0"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["141698\/2018-7"],"award-info":[{"award-number":["141698\/2018-7"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["312559\/2020-8"],"award-info":[{"award-number":["312559\/2020-8"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["311832\/2017-2"],"award-info":[{"award-number":["311832\/2017-2"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["2019\/26310-2"],"award-info":[{"award-number":["2019\/26310-2"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["2017\/26770-8"],"award-info":[{"award-number":["2017\/26770-8"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["2018\/26512-1"],"award-info":[{"award-number":["2018\/26512-1"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["2018\/24037-4"],"award-info":[{"award-number":["2018\/24037-4"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["2018\/23984-0"],"award-info":[{"award-number":["2018\/23984-0"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["2016\/01343-7"],"award-info":[{"award-number":["2016\/01343-7"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["PCEFP3_181243"],"award-info":[{"award-number":["PCEFP3_181243"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The Sound Foundation","award":["support to work of members of the COVID-19 International Modeling (CoMo) Consortium via grant to The University of Oxford (UK)"],"award-info":[{"award-number":["support to work of members of the COVID-19 International Modeling (CoMo) Consortium via grant to The University of Oxford (UK)"]}]}],"content-domain":{"domain":["www.ploscompbiol.org"],"crossmark-restriction":false},"short-container-title":["PLoS Comput Biol"],"abstract":"<jats:p>The SARS-CoV-2 pandemic is a major concern all over the world and, as vaccines became available at the end of 2020, optimal vaccination strategies were subjected to intense investigation. Considering their critical role in reducing disease burden, the increasing demand outpacing production, and that most currently approved vaccines follow a two-dose regimen, the cost-effectiveness of delaying the second dose to increment the coverage of the population receiving the first dose is often debated. Finding the best solution is complex due to the trade-off between vaccinating more people with lower level of protection and guaranteeing higher protection to a fewer number of individuals. Here we present a novel extended age-structured SEIR mathematical model that includes a two-dose vaccination schedule with a between-doses delay modelled through delay differential equations and linear optimization of vaccination rates. By maintaining the minimum stock of vaccines under a given production rate, we evaluate the dose interval that minimizes the number of deaths. We found that the best strategy depends on an interplay between the vaccine production rate and the relative efficacy of the first dose. In the scenario of low first-dose efficacy, it is always better to vaccinate the second dose as soon as possible, while for high first-dose efficacy, the best strategy of time window depends on the production rate and also on second-dose efficacy provided by each type of vaccine. We also found that the rate of spread of the infection does not affect significantly the thresholds of the best window, but is an important factor in the absolute number of total deaths. These conclusions point to the need to carefully take into account both vaccine characteristics and roll-out speed to optimize the outcome of vaccination strategies.<\/jats:p>","DOI":"10.1371\/journal.pcbi.1009978","type":"journal-article","created":{"date-parts":[[2022,3,25]],"date-time":"2022-03-25T13:50:07Z","timestamp":1648216207000},"page":"e1009978","update-policy":"https:\/\/doi.org\/10.1371\/journal.pcbi.corrections_policy","source":"Crossref","is-referenced-by-count":17,"title":["Assessing the best time interval between doses in a two-dose vaccination regimen to reduce the number of deaths in an ongoing epidemic of SARS-CoV-2"],"prefix":"10.1371","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9023-0031","authenticated-orcid":true,"given":"Leonardo","family":"Souto Ferreira","sequence":"first","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5167-705X","authenticated-orcid":true,"given":"Otavio","family":"Canton","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9416-6145","authenticated-orcid":true,"given":"Rafael Lopes Paix\u00e3o","family":"da Silva","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7707-8859","authenticated-orcid":true,"given":"Silas","family":"Poloni","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4815-2092","authenticated-orcid":true,"given":"V\u00edtor","family":"Sudbrack","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5807-3064","authenticated-orcid":true,"given":"Marcelo Eduardo","family":"Borges","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8424-9396","authenticated-orcid":true,"given":"Caroline","family":"Franco","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0510-3992","authenticated-orcid":true,"given":"Flavia Maria Darcie","family":"Marquitti","sequence":"additional","affiliation":[]},{"given":"Jos\u00e9 C\u00e1ssio","family":"de Moraes","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1159-5762","authenticated-orcid":true,"given":"Maria Am\u00e9lia de Sousa Mascena","family":"Veras","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5602-5184","authenticated-orcid":true,"given":"Roberto Andr\u00e9","family":"Kraenkel","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2828-8558","authenticated-orcid":true,"given":"Renato Mendes","family":"Coutinho","sequence":"additional","affiliation":[]}],"member":"340","published-online":{"date-parts":[[2022,3,25]]},"reference":[{"key":"pcbi.1009978.ref001","unstructured":"JCVI. Optimising the COVID-19 vaccination programme for maximum short-term impact; 2021. https:\/\/www.gov.uk\/government\/publications\/prioritising-the-first-covid-19-vaccine-dose-jcvi-statement\/optimising-the-covid-19-vaccination-programme-for-maximum-short-term-impact, [Accessed: 2021-06-18]."},{"key":"pcbi.1009978.ref002","unstructured":"MS. D\u00e9cimo Quinto Informe T\u00e9cnico\u2014Orienta\u00e7\u00f5es T\u00e9cnicas Relativas \u00e0 Continuidade da Campanha Nacional de Vacina\u00e7\u00e3o Contra a COVID-19; 2021. https:\/\/www.gov.br\/saude\/pt-br\/media\/pdf\/2021\/maio\/3\/anexo-decimo-quinto-informe-tecnico.pdf [Accessed: 2021-07-23]."},{"key":"pcbi.1009978.ref003","unstructured":"PHE. COVID-19 vaccination programme\u2014Information for healthcare practitioners; 2021. https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/999527\/COVID-19_vaccination_programme_guidance_for_healthcare_workers_6July2021_v3.9.pdf [Accessed: 2021-07-23]."},{"key":"pcbi.1009978.ref004","unstructured":"Stowe J, Andrews N, Gower C, Gallagher E, Utsi L, Simmons R, et al. Effectiveness of COVID-19 vaccines against hospital admission with the Delta (B.1.617.2) variant; 2021. https:\/\/media.tghn.org\/articles\/Effectiveness_of_COVID-19_vaccines_against_hospital_admission_with_the_Delta_B._G6gnnqJ.pdf [Accessed: 2021-07-26]."},{"issue":"10277","key":"pcbi.1009978.ref005","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S0140-6736(21)00432-3","article-title":"Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials","volume":"397","author":"M Voysey","year":"2021","journal-title":"The Lancet"},{"key":"pcbi.1009978.ref006","article-title":"Efficacy and Safety of a COVID-19 Inactivated Vaccine in Healthcare Professionals in Brazil: The PROFISCOV Study","author":"R Palacios","year":"2021","journal-title":"SSRN Journal Electronic Journal"},{"issue":"27","key":"pcbi.1009978.ref007","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine","volume":"383","author":"FP Polack","year":"2020","journal-title":"New England Journal of Medicine"},{"issue":"7","key":"pcbi.1009978.ref008","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJMoa2108891","article-title":"Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant","volume":"385","author":"JL Bernal","year":"2021","journal-title":"New England Journal of Medicine"},{"key":"pcbi.1009978.ref009","unstructured":"RKI. Epidemiologisches Bulletin 2\/2021; 2021. https:\/\/www.rki.de\/DE\/Content\/Infekt\/EpidBull\/Archiv\/2021\/Ausgaben\/02_21.html [Accessed: 2021-07-26]."},{"key":"pcbi.1009978.ref010","unstructured":"MS. Plano Nacional de Operacionaliza\u00e7\u00e3o da Vacina\u00e7\u00e3o contra Covid-19; 2021. https:\/\/www.gov.br\/saude\/pt-br\/coronavirus\/publicacoes-tecnicas\/guias-e-planos\/plano-nacional-de-vacinacao-covid-19\/view [Accessed: 2021-07-26]."},{"issue":"1","key":"pcbi.1009978.ref011","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.jtbi.2008.02.026","article-title":"A model for influenza with vaccination and antiviral treatment","volume":"253","author":"J Arino","year":"2008","journal-title":"Journal of Theoretical Biology"},{"key":"pcbi.1009978.ref012","doi-asserted-by":"crossref","first-page":"101027","DOI":"10.1016\/j.jocs.2019.101027","article-title":"SIR-based mathematical modeling of infectious diseases with vaccination and waning immunity","volume":"37","author":"M Ehrhardt","year":"2019","journal-title":"Journal of Computational Science"},{"issue":"1","key":"pcbi.1009978.ref013","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.mbs.2005.05.004","article-title":"Vaccination against multiple HPV types","volume":"197","author":"EH Elbasha","year":"2005","journal-title":"Mathematical Biosciences"},{"issue":"2","key":"pcbi.1009978.ref014","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/0025-5564(90)90040-6","article-title":"Vaccination campaigns for common childhood diseases","volume":"100","author":"D Greenhalgh","year":"1990","journal-title":"Mathematical Biosciences"},{"issue":"4","key":"pcbi.1009978.ref015","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1093\/ije\/29.4.744","article-title":"A mathematical model of hepatitis B virus transmission and its application for vaccination strategy in China","volume":"29","author":"S Zhao","year":"2000","journal-title":"International Journal of Epidemiology"},{"key":"pcbi.1009978.ref016","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.epidem.2015.06.001","article-title":"One versus two doses: What is the best use of vaccine in an influenza pandemic?","volume":"13","author":"L Matrajt","year":"2015","journal-title":"Epidemics"},{"key":"pcbi.1009978.ref017","article-title":"Modeling the use of SARS-CoV-2 vaccination to safely relax non-pharmaceutical interventions","author":"ANM Kraay","year":"2021","journal-title":"MedRxiv"},{"issue":"7","key":"pcbi.1009978.ref018","doi-asserted-by":"crossref","first-page":"e1009098","DOI":"10.1371\/journal.pcbi.1009098","article-title":"Projecting contact matrices in 177 geographical regions: An update and comparison with empirical data for the COVID-19 era","volume":"17","author":"K Prem","year":"2021","journal-title":"PLOS Computational Biology"},{"issue":"1","key":"pcbi.1009978.ref019","doi-asserted-by":"crossref","DOI":"10.1038\/s43856-021-00048-6","article-title":"Model-based estimation of transmissibility and reinfection of SARS-CoV-2 P.1 variant","volume":"1","author":"RM Coutinho","year":"2021","journal-title":"Communications Medicine"},{"issue":"6532","key":"pcbi.1009978.ref020","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1126\/science.abe6959","article-title":"Model-informed COVID-19 vaccine prioritization strategies by age and serostatus","volume":"371","author":"KM Bubar","year":"2021","journal-title":"Science"},{"issue":"15","key":"pcbi.1009978.ref021","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1056\/NEJMoa2101765","article-title":"BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting","volume":"384","author":"N Dagan","year":"2021","journal-title":"New England Journal of Medicine"},{"issue":"6538","key":"pcbi.1009978.ref022","doi-asserted-by":"crossref","first-page":"eabg3055","DOI":"10.1126\/science.abg3055","article-title":"Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England","volume":"372","author":"NG Davies","year":"2021","journal-title":"Science"},{"key":"pcbi.1009978.ref023","unstructured":"SVS. Plano Nacional de Operacionaliza\u00e7\u00e3o da Vacina\u00e7\u00e3o contra a COVID-19; 2021. https:\/\/www.gov.br\/saude\/pt-br\/media\/pdf\/2021\/marco\/23\/plano-nacional-de-vacinacao-covid-19-de-2021, [Accessed: 2021-06-03]."},{"key":"pcbi.1009978.ref024","unstructured":"ANVISA. Avalia\u00e7\u00e3o do Uso Emergencial da Vacina CoronaVac\u2014Apresenta\u00e7\u00e3o; 2021. https:\/\/www.gov.br\/anvisa\/pt-br\/assuntos\/noticias-anvisa\/2021\/confira-materiais-da-reuniao-extraordinaria-da-dicol\/1-apresentacao-ggmed-coronavac.pdf [Accessed: 2021-07-21]."},{"key":"pcbi.1009978.ref025","unstructured":"Berkelaar M, Eikland K, Notebaert P. lpSolve: Interface to \u2018Lp_solve\u2019 v. 5.5 to Solve Linear\/Integer Programs; 2020. R package version 5.6.15. Available from: https:\/\/CRAN.R-project.org\/package=lpSolve."},{"issue":"10","key":"pcbi.1009978.ref026","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2107715","article-title":"Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile","volume":"385","author":"A Jara","year":"2021","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"pcbi.1009978.ref027","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/cei.13295","article-title":"Emerging viruses and current strategies for vaccine intervention","volume":"196","author":"B Afrough","year":"2019","journal-title":"Clinical & Experimental Immunology"},{"issue":"7","key":"pcbi.1009978.ref028","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1586\/erv.09.43","article-title":"SARS vaccines: where are we?","volume":"8","author":"RL Roper","year":"2009","journal-title":"Expert Review of Vaccines"},{"issue":"8","key":"pcbi.1009978.ref029","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1038\/s41591-021-01410-w","article-title":"Impact of vaccination on new SARS-CoV-2 infections in the United Kingdom","volume":"27","author":"E Pritchard","year":"2021","journal-title":"Nature Medicine"},{"issue":"10277","key":"pcbi.1009978.ref030","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/S0140-6736(21)00455-4","article-title":"Delayed second dose of the BNT162b2 vaccine: innovation or misguided conjecture?","volume":"397","author":"JFR Robertson","year":"2021","journal-title":"The Lancet"},{"issue":"23","key":"pcbi.1009978.ref031","doi-asserted-by":"crossref","first-page":"5699","DOI":"10.1016\/j.cell.2021.10.011","article-title":"Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine","volume":"184","author":"RP Payne","year":"2021","journal-title":"Cell"},{"key":"pcbi.1009978.ref032","article-title":"Prioritising COVID-19 vaccination in changing social and epidemiological landscapes: a mathematical modelling study","author":"PC Jentsch","year":"2021","journal-title":"The Lancet Infectious Diseases"},{"issue":"6","key":"pcbi.1009978.ref033","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/S1473-3099(21)00143-2","article-title":"Vaccination and non-pharmaceutical interventions for COVID-19: a mathematical modelling study","volume":"21","author":"S Moore","year":"2021","journal-title":"The Lancet Infectious Diseases"},{"issue":"4","key":"pcbi.1009978.ref034","doi-asserted-by":"crossref","first-page":"e3001211","DOI":"10.1371\/journal.pbio.3001211","article-title":"Evaluation of COVID-19 vaccination strategies with a delayed second dose","volume":"19","author":"SM Moghadas","year":"2021","journal-title":"PLOS Biology"},{"key":"pcbi.1009978.ref035","doi-asserted-by":"crossref","first-page":"n1087","DOI":"10.1136\/bmj.n1087","article-title":"Public health impact of delaying second dose of BNT162b2 or mRNA-1273 covid-19 vaccine: simulation agent based modeling study","author":"S Romero-Brufau","year":"2021","journal-title":"BMJ"},{"key":"pcbi.1009978.ref036","article-title":"Managing Two-Dose COVID-19 Vaccine Rollouts with Limited Supply","author":"HY Mak","year":"2021","journal-title":"SSRN Electronic Journal"},{"issue":"11","key":"pcbi.1009978.ref037","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1016\/S1473-3099(21)00289-9","article-title":"Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England (VIVALDI): a prospective cohort study","volume":"21","author":"M Shrotri","year":"2021","journal-title":"The Lancet Infectious Diseases"}],"updated-by":[{"DOI":"10.1371\/journal.pcbi.1009978","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2022,4,6]],"date-time":"2022-04-06T00:00:00Z","timestamp":1649203200000}}],"container-title":["PLOS Computational Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pcbi.1009978","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,6]],"date-time":"2022-04-06T14:00:01Z","timestamp":1649253601000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pcbi.1009978"}},"subtitle":[],"editor":[{"given":"Jennifer A.","family":"Flegg","sequence":"first","affiliation":[]}],"short-title":[],"issued":{"date-parts":[[2022,3,25]]},"references-count":37,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,3,25]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pcbi.1009978","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.07.28.21261200","asserted-by":"object"}]},"ISSN":["1553-7358"],"issn-type":[{"value":"1553-7358","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,25]]}}}